#1 Clinical Trials Search in Europe

(S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt

This article discusses a clinical trial investigating the use of a new drug called FNP-223 in patients with Progressive Supranuclear Palsy (PSP). The study aims to assess the safety, effectiveness, and pharmacokinetics of FNP-223 in slowing the progression of PSP. This Phase 2 trial is randomized, double-blind, and placebo-controlled, involving patients aged 50 to 80 years with possible or probable PSP.

Table of Contents

What is FNP-223?

FNP-223 is a new medication being studied for the treatment of Progressive Supranuclear Palsy (PSP). Its scientific name is (S)-N-(5-(4-(1-(BENZO[D][1,3]DIOXOL-5-YL)ETHYL)PIPERAZIN-1-YL)-1,3,4-THIADIAZOL-2-YL)ACETAMIDE, HYDROCHLORIDE SALT. It comes in the form of a film-coated tablet that is taken orally (by mouth)[1].

What is Progressive Supranuclear Palsy (PSP)?

Progressive Supranuclear Palsy (PSP) is a rare brain disorder that affects movement, balance, and eye control. It is a progressive disease, which means it gets worse over time. PSP can cause problems with walking, balance, speech, swallowing, and vision. The term “supranuclear” refers to the area of the brain affected by the disease, which is above specific clusters of nerve cells called nuclei that control eye movements[1].

Clinical Trial Details

The clinical trial for FNP-223 is called PROSPER. It is a Phase 2 study, which means it is testing how safe and effective the medication is for people with PSP. The study is randomized (participants are assigned to groups by chance), double-blind (neither the participants nor the researchers know who is receiving the actual medication or a placebo), and placebo-controlled (some participants will receive a dummy pill instead of the real medication)[1].

Who Can Participate in the Study?

The study is looking for participants who meet certain criteria, including:

  • Men and women aged 50 to 80 years old
  • Diagnosed with possible or probable PSP-Richardson’s Syndrome (PSP-RS)
  • Have had PSP symptoms for 3 years or less
  • Can walk independently or with minimal assistance
  • Have a caregiver who can accompany them to study visits

There are also several conditions that would prevent someone from participating in the study, such as certain other medical conditions or medications[1].

Study Objectives

The main goals of the study are:

  1. To see if FNP-223 can slow down the progression of PSP over 52 weeks (about 1 year)
  2. To check how safe FNP-223 is when taken for 52 weeks
  3. To understand how the medication affects the severity of PSP symptoms
  4. To see how FNP-223 impacts cognitive function (thinking and memory) and quality of life
  5. To study how the medication is processed in the body (pharmacokinetics)[1]

What Will Be Measured?

The study will use several tools to measure the effects of FNP-223, including:

  • The PSP Rating Scale (PSPRS): This measures the severity of PSP symptoms
  • Clinical Global Impression of Severity (CGI-S): This is the doctor’s assessment of how severe the disease is
  • Patient and Caregiver Global Impression of Severity (PGI-S and CaGI-S): These measure how severe the patient and their caregiver think the disease is
  • Montreal Cognitive Assessment (MoCA): This tests cognitive function
  • PSP Quality of Life scale (PSP-QoL): This measures how PSP affects quality of life[1]

Potential Benefits and Risks

While FNP-223 shows promise in potentially slowing the progression of PSP, it’s important to remember that this is still an experimental drug. The study aims to determine if it is safe and effective. As with any clinical trial, there may be risks and side effects that are not yet known.

Participants in the study will be closely monitored for any side effects or changes in their condition. The study will also look at how FNP-223 affects things like blood tests, heart function (ECG), and mental health[1].

If you or a loved one has PSP and is interested in this study, it’s important to discuss it with your healthcare provider. They can help you understand if you might be eligible and whether participating in the study could be right for you.

Aspect Details
Study Type Randomized, double-blind, placebo-controlled, Phase 2
Drug Name FNP-223
Condition Progressive Supranuclear Palsy (PSP)
Main Objectives Assess efficacy in slowing PSP progression, evaluate safety and tolerability
Duration 52 weeks
Age Range 50 to 80 years
Key Inclusion Criteria PSP diagnosis, symptoms ≤3 years, PSPRS score ≤40, ability to walk with minimal assistance
Primary Endpoints Change in PSPRS score, safety assessments
Secondary Endpoints Changes in global impression scales, quality of life, cognitive function

FAQ

  • What is Progressive Supranuclear Palsy (PSP)? Progressive Supranuclear Palsy (PSP) is a rare brain disorder that affects movement, balance, and eye control. It is a progressive condition, meaning symptoms worsen over time.
  • What is FNP-223? FNP-223 is a new drug being tested to potentially slow the progression of PSP. It is given as a film-coated tablet and taken orally.
  • Who can participate in this clinical trial? The trial is open to men and women aged 50 to 80 years who have been diagnosed with possible or probable PSP for 3 years or less. Participants must meet specific criteria, including a certain score on the PSP Rating Scale and the ability to walk with minimal assistance.
  • How long does the trial last? The trial lasts for 52 weeks (1 year), during which participants will receive either FNP-223 or a placebo.
  • What are the main goals of this clinical trial? The main goals are to assess how well FNP-223 slows PSP progression, evaluate its safety and tolerability, and understand how the drug moves through the body (pharmacokinetics) in PSP patients.

Ongoing Clinical Trials on (S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt

  • Study of FNP-223 tablets to slow disease progression in patients with Progressive Supranuclear Palsy (PSP)

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France Germany Hungary Italy Poland Portugal +1

Glossary

  • Progressive Supranuclear Palsy (PSP): A rare brain disorder that affects movement, balance, and eye control, progressively worsening over time.
  • FNP-223: The new drug being tested in this clinical trial to potentially slow PSP progression.
  • Randomized: A method of assigning participants to different groups by chance, like flipping a coin.
  • Double-blind: Neither the participants nor the researchers know who is receiving the actual drug or the placebo during the study.
  • Placebo-controlled: Some participants receive an inactive substance (placebo) instead of the actual drug to compare results.
  • Phase 2 study: A stage of clinical research that tests a drug's effectiveness and safety in a larger group of people with the condition.
  • Efficacy: How well a treatment works to produce the desired effect.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • PSP Rating Scale (PSPRS): A tool used to measure the severity and progression of PSP symptoms.
  • Inclusion criteria: Specific factors that allow a person to participate in a clinical trial.
  • Exclusion criteria: Factors that prevent a person from participating in a clinical trial.
  • Adverse events: Unexpected or harmful events that occur during a clinical trial.
  • Caregiver: A person who provides support and assistance to the study participant.

References

  1. http://clinicaltrials.eu/trial/study-on-fnp-223-for-slowing-progressive-supranuclear-palsy-in-patients/